Nexsen Moves to Expand GBS Diagnostics With FlashDx Joint Venture

Nexsen Limited has formed a 50:50 joint venture with FlashDx Shenzhen Inc. to develop and commercialise an enhanced molecular Group B Streptococcus diagnostic test targeting US FDA and European regulatory approvals, aiming to expand their presence in hospital and intrapartum molecular testing across the Asia-Pacific region.

This Wire brief sits within Fusion42's coverage of Medtech.